Evidence map›Paper›PMID 39321216›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

A Novel Human SDHA-Knockout Cell Line Model for the Functional Analysis of Clinically Relevant SDHA Variants.

Jason D Kent, Lillian R Klug, Michael C Heinrich

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Multiplex, multimodal mapping of variant effects in secreted proteins.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jason D KentPortland VA Health Care System and OHSU Knight Cancer Institute, Portland, Oregon.ORCID 0000-0001-7431-7877
Lillian R KlugPortland VA Health Care System and OHSU Knight Cancer Institute, Portland, Oregon.ORCID 0000-0003-0520-8241
Michael C HeinrichPortland VA Health Care System and OHSU Knight Cancer Institute, Portland, Oregon.ORCID 0000-0003-3790-0478

Funding

National Succinate Dehydrogenase-deficient GIST Translational Research and Clinical Trial ConsortiumU01CA278470 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOHN Walter GLOD, Jason Keith Sicklick · 2024 to 2026
$1.8M
Novel models for functional profiling of germline SDH variants associated with cancerR21CA263400 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HEINRICH, MICHAEL C · 2021 to 2022
$320k
Functional profiling of germline SDH variants associated with cancer susceptibilityI01BX005358 · VA · PORTLAND VA MEDICAL CENTER · PI HEINRICH, MICHAEL C · 2021 to 2025
–
BLRD VA I01 BX005358GIST Cancer Research Fund (GCRF)National Cancer Institute (NCI) R21CA263400National Cancer Institute (NCI) U01 CA278470-01A1NCI NIH HHS R21 CA263400NCI NIH HHS U01 CA278470U.S. Department of Veterans Affairs (VA) I01BX005358
6 · The paper itself

Abstract

purposeSDHA mutations are the most common cause of succinate dehydrogenase (SDH)-deficient GIST. Enhanced cancer surveillance of individuals carrying a known pathogenic germline SDHA mutation has the potential to detect early-stage tumors, allowing for improved patient outcomes. However, more than 95% of the >1,000 SDHA missense variants listed in ClinVar are variants of uncertain significance. Our ability to interpret the significance of SDHA variants must improve before genetic sequencing can be utilized to its full potential. EXPERIMENTAL

designSDHA variants were introduced into a clonal SDHA-knockout cell line via Bxb1-mediated recombination. SDH activity and SDHA abundance were determined for each variant, and logistic regression analysis was used to derive functional evidence for clinical variant interpretation.

resultsOur analysis revealed that cancer-associated SDHA missense variants can be clearly distinguished from noncancer variants according to the extent of SDH dysfunction caused. As such, SDH activity data can be used to predict cancer pathogenicity with strong performance metrics, exceeding those of computational prediction tools. From these data, we obtained functional evidence for clinical variant interpretation from 21 of 22 assayed variants of uncertain significance, with 19 in favor of cancer pathogenicity and two against pathogenicity. Lastly, simulating the addition of our functional evidence with limited preexisting evidence allowed for 18 of 22 variants to be reclassified.

conclusionsWe describe a novel pipeline for investigating the functional consequences of SDHA missense variants. In total, we characterized 72 variants, developed criteria for obtaining functional evidence, and demonstrated the potential of this evidence for clinical variant interpretation.

Indexed as

Mutation, MissenseCell LineElectron Transport Complex IIGene Knockout TechniquesGenetic Predisposition to DiseaseGerm-Line MutationHumansNeoplasmsSuccinate DehydrogenaseElectron Transport Complex IISDHA protein, humanSuccinate Dehydrogenase

Identifiers

PMID39321216
PMCPMC11611653

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.